97 related articles for article (PubMed ID: 11924802)
1. Rhesus macaque model for ovarian cancer chemoprevention.
Brewer M; Baze W; Hill L; Utzinger U; Wharton JT; Follen M; Khan-Dawood F; Satterfield W
Comp Med; 2001 Oct; 51(5):424-9. PubMed ID: 11924802
[TBL] [Abstract][Full Text] [Related]
2. Biomarker modulation in a nonhuman rhesus primate model for ovarian cancer chemoprevention.
Brewer M; Utzinger U; Satterfield W; Hill L; Gershenson D; Bast R; Wharton JT; Richards-Kortum R; Follen M
Cancer Epidemiol Biomarkers Prev; 2001 Aug; 10(8):889-93. PubMed ID: 11489756
[TBL] [Abstract][Full Text] [Related]
3. Combination of 4-HPR and oral contraceptive in monkey model of chemoprevention of ovarian cancer.
Brewer M; Ranger-Moore J; Satterfield W; Hao Z; Wang J; Brewer E; Wharton JT; Bast R; Zou C
Front Biosci; 2007 Jan; 12():2260-8. PubMed ID: 17127462
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical expression of molecular markers in an avian model: a potential model for preclinical evaluation of agents for ovarian cancer chemoprevention.
RodrÃguez-Burford C; Barnes MN; Berry W; Partridge EE; Grizzle WE
Gynecol Oncol; 2001 Jun; 81(3):373-9. PubMed ID: 11371125
[TBL] [Abstract][Full Text] [Related]
5. In vitro model of normal, immortalized ovarian surface epithelial and ovarian cancer cells for chemoprevention of ovarian cancer.
Brewer M; Wharton JT; Wang J; McWatters A; Auersperg N; Gershenson D; Bast R; Zou C
Gynecol Oncol; 2005 Aug; 98(2):182-92. PubMed ID: 15907982
[TBL] [Abstract][Full Text] [Related]
6. Fluorescence spectroscopy as a biomarker in a cell culture and in a nonhuman primate model for ovarian cancer chemopreventive agents.
Brewer M; Utzinger U; Li Y; Atkinson EN; Satterfield W; Auersperg N; Richards-Kortum R; Follen M; Bast R
J Biomed Opt; 2002 Jan; 7(1):20-6. PubMed ID: 11818008
[TBL] [Abstract][Full Text] [Related]
7. Prevention of ovarian cancer.
Brewer MA; Mitchell MF; Bast RC
In Vivo; 1999; 13(1):99-106. PubMed ID: 10218141
[TBL] [Abstract][Full Text] [Related]
8. Ovarian morphology after administration of an oral contraceptive. An investigation in the rhesus monkey.
Vooys GP
Eur J Obstet Gynecol Reprod Biol; 1974; 4(1 SUPPL):S45-9. PubMed ID: 4472225
[No Abstract] [Full Text] [Related]
9. [Chemoprevention and prophylactic surgery in ovarian carcinoma].
Deffieux X; Touboul C; Uzan C; Faivre E; Frydman R; Fernandez H; Morice P
J Gynecol Obstet Biol Reprod (Paris); 2007 Dec; 36(8):756-63. PubMed ID: 17719183
[TBL] [Abstract][Full Text] [Related]
10. A phase I-II preoperative biomarker trial of fenretinide in ascitic ovarian cancer.
Colombo N; Formelli F; Cantù MG; Parma G; Gasco M; Argusti A; Santinelli A; Montironi R; Cavadini E; Baglietto L; Guerrieri-Gonzaga A; Viale G; Decensi A
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1914-9. PubMed ID: 17035399
[TBL] [Abstract][Full Text] [Related]
11. Minimally invasive surgery via laparoscopy for intra-abdominal biopsy in obese rhesus macaques (Macaca mulatta).
Liao P; Bodkin N; Cho E; Alexander T; Ortmeyer H
Comp Med; 2004 Apr; 54(2):159-64. PubMed ID: 15134360
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of 4-(N-hydroxyphenyl)retinamide conjugated with poly(L-glutamic acid) against ovarian cancer xenografts.
Zou C; Brewer M; Cao X; Zang R; Lin J; Deng Y; Li C
Gynecol Oncol; 2007 Dec; 107(3):441-9. PubMed ID: 17854871
[TBL] [Abstract][Full Text] [Related]
13. Endogenous fluorescence spectroscopy of cell suspensions for chemopreventive drug monitoring.
Kirkpatrick ND; Zou C; Brewer MA; Brands WR; Drezek RA; Utzinger U
Photochem Photobiol; 2005; 81(1):125-34. PubMed ID: 15535738
[TBL] [Abstract][Full Text] [Related]
14. The monkey, the hen, and the mouse: models to advance ovarian cancer chemoprevention.
Lu KH; Yates MS; Mok SC
Cancer Prev Res (Phila); 2009 Sep; 2(9):773-5. PubMed ID: 19737981
[TBL] [Abstract][Full Text] [Related]
15. A pilot study to establish a clinical model to perform phase II studies of breast cancer chemopreventive agents in women at high risk with biomarkers as surrogate endpoints for activity.
Stearns V; Gallagher A; Kleer CG; Singh B; Freedman M; Haddad BR; Isaacs C; Warren R; Brown M; Cullen J; Trock B; Hayes DF
Clin Cancer Res; 2004 Dec; 10(24):8332-40. PubMed ID: 15623610
[TBL] [Abstract][Full Text] [Related]
16. The risk of breast, endometrial and ovarian cancer in users of hormonal preparations.
Bernstein L
Basic Clin Pharmacol Toxicol; 2006 Mar; 98(3):288-96. PubMed ID: 16611204
[TBL] [Abstract][Full Text] [Related]
17. Three new potential ovarian cancer biomarkers detected in human urine with equalizer bead technology.
Petri AL; Simonsen AH; Yip TT; Hogdall E; Fung ET; Lundvall L; Hogdall C
Acta Obstet Gynecol Scand; 2009; 88(1):18-26. PubMed ID: 19023702
[TBL] [Abstract][Full Text] [Related]
18. Feasibility of performing chemoprevention trials in women at elevated risk of ovarian carcinoma: initial examination of celecoxib as a chemopreventive agent.
Barnes MN; Chhieng DF; Dreher M; Jones JL; Grizzle WE; Jones L; Talley L; Partridge EE
Gynecol Oncol; 2005 Sep; 98(3):376-82. PubMed ID: 15993933
[TBL] [Abstract][Full Text] [Related]
19. Surrogate end-point biomarker analysis in a retinol chemoprevention trial in current and former smokers with bronchial dysplasia.
Lam S; Xu X; Parker-Klein H; Le Riche JC; Macaulay C; Guillaud M; Coldman A; Gazdar A; Lotan R
Int J Oncol; 2003 Dec; 23(6):1607-13. PubMed ID: 14612933
[TBL] [Abstract][Full Text] [Related]
20. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis.
Lu KH; Patterson AP; Wang L; Marquez RT; Atkinson EN; Baggerly KA; Ramoth LR; Rosen DG; Liu J; Hellstrom I; Smith D; Hartmann L; Fishman D; Berchuck A; Schmandt R; Whitaker R; Gershenson DM; Mills GB; Bast RC
Clin Cancer Res; 2004 May; 10(10):3291-300. PubMed ID: 15161682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
